Semax Protocol: Why a Clinic Protocol Is Not a Trial

In research, a protocol is a binding document written before anything happens. It states what will be measured, in whom, against what comparison, for how long, and what would count as the result being negative. It is filed, it is reviewed by an ethics committee, and departing from it has to be declared. Its power comes from being fixed in advance, because a plan written before the data exists cannot be adjusted to flatter the outcome.

In private practice, a protocol is a plan of what a provider intends to do with a client. It can be sensible, it can be written by an experienced clinician, and it can be revised at any point without anyone being told. It commits nobody to a prespecified outcome, because it was never framed as a test of anything.

Both meanings are legitimate in their own settings. The trouble starts when a document written in the second sense is read as though it were the first, and there are commercial reasons for a page to encourage exactly that reading.

Set out plainly, the obligations are heavier than most readers realise.

A prespecified primary outcome, chosen before results exist. A comparison group, so that improvement can be separated from time passing. Blinding wherever the outcome is judged rather than measured, which for anything cognitive is essential rather than optional. Defined eligibility, so the population is knowable. A stopping rule. A registration entry that exists publicly whether or not the results are flattering. And a plan for reporting harms that does not depend on the sponsor volunteering them.

For this compound, no such registered Western document exists. There is no interventional trial registration to open, no prespecified endpoint to read, and no results entry to check against what a seller claims. That absence is the background against which every private document about it is written.

Read the last column downward and the pattern is clear enough. The clinic document may be careful and well intentioned. It is structurally incapable of producing evidence, because none of the features that turn a plan into a test are present in it.

This is where the compound differs from most things sold the same way, and where a reader needs to be most careful.

Semax is a registered medicine in Russia. A marketer saying it is an approved medicine is not lying. That single fact does more work in a sales page than anything else available, because the reader hears approved and supplies the rest from their own country's meaning of the word.

Two things are worth separating. The first is that an approval is territorial by design. Authorities do not recognise each other automatically, because they differ in what evidence they require and how they weigh it. A licence granted in Russia hands a defined set of protections to someone standing in a Russian pharmacy, and hands nothing at all to someone ordering online from Bristol or Denver.

The second is subtler and matters more. The evidence behind that registration is real, and much of it is not retrievable in the way a Western reader is used to. Human clinical work exists. It is largely published in Russian, it is not sitting in a trial registry with prespecified outcomes an English speaker can audit, and it describes a licensed preparation used inside a supervised system rather than a vial ordered online.

So the accurate position has two halves and both are uncomfortable. Anyone telling you this compound has never been studied in people is wrong. Anyone telling you the Russian registration is equivalent to a Western approval, or that it means anything about the vial your provider hands you, is also wrong. A protocol that cites the approval and stops there is using the first half to sell you past the second.

Look at what the document says about liability, and compare it with what the same clinic's website says about results.

A plan usually carries language placing responsibility for use on the client, sometimes describing the material as research grade or not for human consumption. That line is doing real legal work. The marketing copy describing outcomes is doing no legal work at all. When those two sit on the same site, only one of them would matter if you needed it to.

This is not a reason to distrust every provider. It is a reason to read the two documents together rather than separately, because the gap between them tells you how the practice sees the arrangement even when the consultation felt otherwise.

It would be easy to read all of this as an argument that a clinic document is worthless. It is not, and the distinction matters if you are choosing between providers.

The consultation behind the plan can be valuable in ways that have nothing to do with the compound. A history that surfaces a condition making any centrally acting substance a bad idea. A review of your current prescriptions by someone qualified to reason about interactions. A conversation about whether the fatigue or concentration complaint has a cause worth investigating properly, which is the question a supplier will never ask you. A named person who remains contactable if something goes wrong, and who has a professional reputation attached to how they respond.

Those are real services and they justify a real fee. They are also the parts of the offer least likely to appear in the marketing, because they sound less impressive than a schedule.

The failure mode is paying for the document and receiving only the document. If the encounter consists of a short intake form, a plan generated from a template and a vial in the post, you have bought a supplier relationship with a clinical costume on it. That is a straightforward consumer question you can ask before handing over money: what exactly does the consultation involve, and who conducts it.

A short list, and it is achievable.

It would name the supplier and the batch, and attach the testing that batch actually received. It would say which claims come from work in rats or cell culture and which come from human use, and it would say where that human use took place and under what regulatory system. It would state the absence of any Western registration plainly rather than leaving it to inference. It would describe what the provider will do if something goes wrong, including who to contact and what gets reported where.

None of that would make the compound proven. It would make the document honest about which kind of thing it is, which is the most any private plan can offer while the underlying evidence remains where it is: real in one country, unavailable for inspection in yours, and absent from the registries a consumer can actually search.